in Malaysia. METHODS: A non-parametric method called Data Envelopment Analysis (DEA) with two assumptions : Variable Return to Scale (VRS) and Constant Return to Scale (CRS), was used to calculate and compare the effi ciency scores for selected hospitals' clinical departments between the year 1998 and 2006. DEA input oriented analysis indicates how the ineffi cient units could adjust their inputs to reach the efficiency frontier. RESULTS: Based on CRS model the mean effi ciency scores in Hospital A departments were 76%. One department was around 50% and six departments were between 50% and 90% and three departments were more than 90%. The mean effi ciency scores in Hospital B was 92%. In this hospital, two departments were between 75% and 90% and two departments had effi ciency score equal 100% during study period. In Hospital C all departments were more than 75% and one department had effi ciency score equals 100%. The results based on VRS model showed similar trends. CONCLUSIONS: The mean of effi ciency score according different assumptions of Hospital B was higher than two other hospitals. The results showed that few departments are effi cient and rests are considered ineffi cient and need to fi nd optimum mixture of inputs combination. It is suggested that Hospital A and Hospital C should consider to improve their management of the resource inputs in ineffi cient department in order to enhance their effi ciencies.
PHP38 COMPLEXITY INCREASES UNCERTAINTY: THE IMPACT OF PBAC GUIDELINES (VERSION 4) ON PBAC DECISION-MAKING
Chollet M, Lindsay P, Gonzalo F Sanofi -Aventis Australia, Macquarie Park, Australia OBJECTIVES: In Australia, the Pharmaceutical Benefi ts Advisory Committee (PBAC) makes recommendations to the Minister for Health on the reimbursement of pharmaceuticals. The sponsor's submission is accepted by the PBAC if the drug is determined to be clinically effective and also cost-effective. New PBAC Guidelines on how to prepare a submission (version 4) were introduced in 2008. These new Guidelines sought to reduce the uncertainty for the PBAC in accepting the many inferences made in major submissions. We assessed whether the New Guidelines have indeed reduced the PBAC's uncertainty in their decision-making. METHODS: Since June 2003 all PBAC recommendations have been made public on the Department of Health & Ageing website. Public Summary Documents (PSD) are available for PBAC considerations relating to the PBS listing of medicines since July 2005 meeting. We reviewed all the PSDs reported during the period of July 2005 to July 2009. For each PSD, we estimated the average number of times that the words "uncertain/uncertainties/uncertainty" appear per PSD page. We compared the results for the period before and after the introduction of version 4 of the PBAC Guidelines. RESULTS: The average number of times that the words "uncertain/uncertainties/uncertainty" appeared per PSD page was signifi cantly higher for the period after the introduction of version 4 of the PBAC Guidelines compared to the period before (0.51 vs. 0.66, P < 0.00001). CONCLU-SIONS: The introduction of version 4 of the PBAC Guidelines in 2008 has led to an increase in the complexity and, thus, uncertainty faced by PBAC during their deliberations around reimbursement of pharmaceuticals in Australia. There was a signifi cant 30% increase in the number of times that the word "uncertain/uncertainties/uncertainty" was found per PSD page compared with the period prior to the introduction of the version 4 of the Guidelines (2003 Guidelines ( -2008 .
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PHP39 THE EFFECTS OF DIRECT BILLING SYSTEM IN PATIENTS WITH CIVIL-SERVANT MEDICAL BENEFIT SCHEMES ON PRESCRIBING PATTERNS
Dilokthornsakul P, Chaiyakunapruk N, Nimpitakpong P Naresuan University, Muang, Phitsanulok, Thailand OBJECTIVES: In 2006, the reimbursement system for civil-servant medical benefi t schemes benefi ciaries in Thailand was changed to direct billing system. It was unknown how this new system affects drug expenditures and the number of drug supply given to benefi ciaries. This study aims to assess the effects of direct billing system on prescribing patterns. METHODS: This study was undertaken with retrospective cohort approach. We used the data recorded in databases of a university hospital in northern part of Thailand. We undertook the data on all patients with civil-servant medical benefi t schemes who came to out-patients department between October 1, 2005 and March 31, 2007. Mean cost of medication, number of days' supplies and medication possession ratio (MPR) of fi ve highest costs of oral medication were calculated in 1 year before and after the system was changed. RESULTS: Out of 43,897 visits made at the hospital, 15,632 (36%) were under civil-servant medical benefi t schemes. Eighty-eight percent (13,785/15,632) received medications during visit. The total costs of medication increased from 2 million to 4 million baths in 1 year. Glucosamine, atorvastatin, rosiglitazone, clopidogrel and diacerin were highest used in terms of drug cost. Averages of day's supplies based on these medications increased from 1.29 to 1.48 months per a prescription. Proportion of patients receiving medications more than 3 months, was slightly increased from 1.82% to 2.43%. Three out of fi ve medications had higher MPR after system was changed (Relative risk ranged on 1.19-2.32). Two of these were statistical signifi cant. CONCLUSIONS: The direct billing system affects prescribing patterns as indicated by trend of increased number of day's supplies and higher medication possession ratio. Further evidence remains needed. Policymakers need to consider all relevant and important consequences associated with the new system prior to making policy decision-making.
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PIH1 CRITICAL APPRAISAL OF SYSTEMATIC REVIEWS ASSESSING SAFETY OUTCOMES OF SSRIS IN THE PERINATAL PERIOD
Merlo GB, Elliot L, Campbell S, Norris S Health Technology Analysts Pty Ltd, Sydney, NSW, Australia OBJECTIVES: A systematic appraisal was conducted of published systematic reviews that assessed the harms associated with selective serotonergic reuptake inhibitors (SSRIs) in the perinatal period, both for the mother and infant. METHODS: A systematic method of literature searching and selection was employed for this review. Searches were conducted in EMBASE, Medline and the Cochrane Database of Systematic Reviews. Studies were eligible if they evaluated pregnancy or infant-related safety outcomes for SSRI use in pregnant or lactating women. RESULTS: The literature search identifi ed seventeen systematic reviews and three subsequently published prospective cohort studies. None of the systematic reviews assessing serotonergic antidepressants as a group found an association with congenital malformations. An association between paroxetine exposure and infant cardiovascular malformations has been reported in the literature; however, more recent evidence from a large systematic review shows no relationship between paroxetine exposure and congenital cardiac malformations. Neonatal symptoms (such as withdrawal symptoms, lower Apgar score, and diminished response to pain stimulus) have been reported in 20-30% of infants with third trimester SSRI exposure. All of the reviews reported the symptoms as mild and self-limiting. Several SRs found a signifi cant association between SSRI use in pregnancy and premature delivery, low birthweight, and admission to special care nurseries. There is confl icting evidence regarding the long-term neurodevelopmental risks of serotonergic antidepressants. Although the levels of SSRIs in breast milk are relatively low, the evidence for the safety of antidepressant exposure via breastfeeding is limited. CONCLUSIONS: SSRI exposure during pregnancy is associated with mostly minor and temporary adverse outcomes for the newborn. The risk of these outcomes needs to be balanced with the risk of adverse outcomes resulting from SSRI withdrawal for the mother. 
